Accurate Education - Omega-3 Fatty Acids for Chronic Pain: A Patient Guide

Nutraceuticals:

Omega-3 Fatty Acids for Chronic Pain: A Patient Guide

Omega-3 fatty acids, particularly EPA and DHA from fish oil, are effective natural anti-inflammatory agents. Daily supplementation of these fatty acids effectively reduce chronic pain, joint tenderness, and stiffness associated with conditions like arthritis. They function by inhibiting inflammatory pathways and producing compounds that resolve inflammation.

See:

Nutraceutical Patient Guides:

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

Omega-3 Fatty Acids for Chronic Pain: A Patient Guide

1. OVERVIEW

Omega-3 fatty acids are essential polyunsaturated fats that the body cannot produce and must be obtained through diet or supplementation. The two most biologically active forms are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), found primarily in fatty fish and fish oil supplements.[1][2]

What makes omega-3 fatty acids valuable for chronic pain:

Inhibit production of pro-inflammatory prostaglandins and leukotrienes from arachidonic acid[1][2][3]
Serve as precursors to specialized pro-resolving mediators (SPMs)—resolvins, protectins, and maresins—that actively resolve inflammation[4][5][6]
Suppress NF-κB activation, reducing inflammatory gene expression[7][8]
Modulate microglial activation and neuroinflammation in the spinal cord[9][10][11]
Inhibit vesicular nucleotide transporter (VNUT), reducing ATP-mediated pain signaling[12]
Activate PPAR-γ, an anti-inflammatory transcription factor[7]

How Omega-3 Fatty Acids Compare to Conventional Medications:

A 2025 meta-analysis of 41 randomized controlled trials (n=3,759) found omega-3 fatty acids produced a moderate, clinically significant reduction in chronic pain (SMD -0.55, 95% CI -0.76 to -0.34), with benefits increasing over time—from SMD -0.27 at 1 month to SMD -0.83 at 6 months.[13] Meta-analyses in rheumatoid arthritis demonstrate that high-dose omega-3 supplementation (1.7-9.6 g/day) reduces morning stiffness and joint pain, with some patients able to reduce NSAID use.[14][15]

Unlike NSAIDs, omega-3 fatty acids do not cause gastrointestinal ulceration, cardiovascular risks, or renal toxicity with long-term use.[16][17] However, the onset of benefit is slower (weeks to months) compared to the immediate relief from NSAIDs.

—

2. DIETARY SOURCES

EPA and DHA are found primarily in marine sources, with content varying significantly:

High EPA/DHA Foods (per 100g serving):

Atlantic mackerel: 2.5-2.7 g EPA+DHA[16]
Atlantic salmon (wild): 1.8-2.2 g EPA+DHA[16]
Herring: 1.7-2.0 g EPA+DHA[16]
Sardines: 1.4-1.8 g EPA+DHA[16]
Anchovies: 1.4-1.7 g EPA+DHA[16]
Rainbow trout: 1.0-1.2 g EPA+DHA[16]
Albacore tuna: 0.7-1.0 g EPA+DHA[16]
Oysters: 0.4-0.6 g EPA+DHA[16]

Plant Sources (Alpha-Linolenic Acid/ALA):

Flaxseed oil: 7.3 g ALA per tablespoon[16][18]
Chia seeds: 5.0 g ALA per ounce[16]
Walnuts: 2.6 g ALA per ounce[16]

Important Bioavailability Notes:

ALA conversion to EPA/DHA is very limited (approximately 5-10% to EPA, 5% to DHA), making plant sources inadequate for therapeutic purposes.[18][19]
EPA and DHA from fish are directly bioavailable and do not require conversion.[20]
Krill oil may have better bioavailability than fish oil due to phospholipid-bound omega-3s and contains the antioxidant astaxanthin.[21][22]
Microalgae-derived omega-3s provide comparable bioavailability to fish oil and are suitable for vegetarians/vegans.[23]
Taking omega-3 supplements with a fat-containing meal enhances absorption.[20]
Average Western dietary intake provides only 100-200 mg/day of EPA+DHA, far below therapeutic doses of 2-4 g/day needed for anti-inflammatory effects.[24]

—

3. INDICATIONS FOR NUTRACEUTICAL SUPPLEMENTATION

Pain Conditions with Human Clinical Evidence:

Rheumatoid Arthritis – MODERATE-HIGH Quality Evidence

Meta-analysis of 30 RCTs showed significant improvement in pain, tender joint count, swollen joint count, DAS28, and HAQ scores[25]
Doses >2 g/day of animal-derived omega-3s for 3-6 months show greatest benefit[25]
May reduce NSAID use in some patients[15]
Reduces tender joint count significantly (SMD -0.59)[26]

Migraine – MODERATE Quality Evidence

High-quality showed dietary omega-3 intervention reduced headache days by 4 days/month and headache hours by 1.7 hours/day compared to control[27]
12-week RCT of 1.8 g/day EPA reduced monthly migraine days by 4.4 days vs. 0.6 days with placebo[28]
Benefits enhanced when combined with reduced omega-6 (linoleic acid) intake[27]

Dysmenorrhea (Menstrual Pain) – MODERATE Quality Evidence

-Meta-analysis showed omega-3s reduce severity of primary dysmenorrhea [29]
Largest effect size among all chronic pain conditions studied [30]
May reduce need for rescue analgesics (ibuprofen)[31]

Pain Conditions with Mixed/Emerging Evidence:

Osteoarthritis – LOW-MODERATE Quality Evidence

2024 JAMA RCT: 2 g/day krill oil showed no significant benefit over placebo for knee pain[21]
Earlier RCT: 4 g/day krill oil showed modest improvements in pain, stiffness, and function[22]
Preclinical evidence supports anti-inflammatory and chondroprotective effects[32][33]
Higher doses (>3 g/day) may be needed for clinical benefit

Neuropathic Pain – LOW Quality Evidence

Cochrane review found inadequate data to draw conclusions about diabetic neuropathy[34]
Pilot studies suggest DHA-rich supplementation may reduce painful diabetic neuropathy symptoms[35][36]
Strong preclinical evidence for analgesic effects via opioid system activation[37]
EPA inhibits VNUT, a novel target for neuropathic pain[12]

—

4. OMEGA-3’S IMPACT ON PAIN CONDITIONS

Omega-3 fatty acids address the underlying pathophysiology of chronic pain through multiple mechanisms:

Anti-Inflammatory Actions:

Compete with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, reducing pro-inflammatory prostaglandins and leukotrienes[1][2][3]
EPA produces less inflammatory eicosanoids (3-series prostaglandins, 5-series leukotrienes) than arachidonic acid[2][24]
Suppress NF-κB activation, reducing inflammatory gene transcription[7][8]
Reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)[38][39]
Decrease adhesion molecule expression and leukocyte chemotaxis[2][24]

Pro-Resolution Actions (Specialized Pro-Resolving Mediators):

EPA and DHA are precursors to resolvins (RvE1, RvD1), protectins, and maresins[4][5][6]
These SPMs actively resolve inflammation rather than simply suppressing it[4][10]
SPMs promote clearance of inflammatory debris and tissue repair[5][6]
May explain time-dependent improvement in pain outcomes[13]

Joint-Protective Effects:

Reduce cartilage degradation markers in preclinical models[32][33]
Inhibit matrix metalloproteinases[33]
Modulate synovial inflammation[32]

—

5. OMEGA-3’S IMPACT ON PAIN PROCESSING

Pain processing refers to how pain signals are processed from the initial damaged tissue source of pain through the nerves and spinal cord to the brain and then down the spinal cord again. Omega-3 fatty acids offer potential benefit for reducing the severity of the pain experience by acting at various levels of pain processing.

Level 1: Peripheral Pain Receptor (Nociception Transduction)

Reduce prostaglandin E2 production at sites of tissue injury[1][2]
Decrease peripheral sensitization of nociceptors[4][5]
Generate resolvins that directly inhibit TRPV1 and TRPA1 channels on sensory neurons[5]

Level 2: Primary Afferent Transmission to Spinal Cord

EPA inhibits vesicular nucleotide transporter (VNUT) in sensory neurons, reducing ATP release[12]
Protect dorsal root ganglion neurons from inflammatory damage[35][40]
Reduce P2X receptor-mediated pain signaling[12]

Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)

DHA attenuates spinal cord microglial activation[11]
Inhibit p38 MAPK phosphorylation in spinal microglia[11]
Reduce spinal cord production of TNF-α, IL-1β, and IL-6[11]
Suppress glial-mediated neuroinflammation[9][10]

Level 4: Ascending Spinal Pathways and Supraspinal Processing

Provide neuroprotection through anti-inflammatory mechanisms[9][41]
Reduce neuroinflammation in ascending pain pathways[10][41]

Level 5: Brain Cortical Processing and Pain Perception

DHA is a major structural component of brain phospholipids[9]
Modulate microglial phenotype toward anti-inflammatory state[9][42]
May improve cognitive function affected by chronic pain[9]

Level 6: Descending Pain Modulation

Acute analgesic effects may involve opioid system activation[37]
Reduce central inflammatory processes that impair descending inhibition[9][10]

—

6. BENEFITS FOR PAIN SENSITIZATION

Peripheral Sensitization: MODERATE Quality Evidence

Reduce prostaglandin-mediated sensitization of peripheral nociceptors[1][2]
Generate resolvins that directly inhibit TRP channel sensitization[5]
Decrease inflammatory cytokines at sites of tissue injury[2][3]
Prevent development of hyperalgesia in preclinical models[40]

Central Sensitization: MODERATE Quality Evidence

Suppress spinal cord microglial and astrocyte activation[9][10][11]
Inhibit p38 MAPK signaling in spinal cord[11]
Reduce spinal cord cytokine production[11]
DHA attenuates carrageenan-induced central sensitization[11]
Omega-3 deficiency associated with enhanced central sensitization in animal models[41]

—

7. OMEGA-3’S IMPACT ON THE 4 DRIVING FORCES OF CHRONIC PAIN

1. Systemic Inflammation: STRONG EFFECT

Meta-analysis: EPA+DHA doses of 1-3 g/day significantly reduce CRP, TNF-α, and IL-6[38]
Inhibit NF-κB activation, the master regulator of inflammatory gene expression[7][8]
Reduce arachidonic acid-derived pro-inflammatory eicosanoids[1][2][3]
DHA more effective than EPA for reducing IL-18 and increasing adiponectin[39]
Effects are dose-dependent and time-dependent[38]

2. Neuroinflammation: STRONG EFFECT (Primarily Preclinical)

Suppress microglial activation through SIRT1 pathway[42]
Reduce neuroinflammatory cytokine production in CNS[9][10]
DHA inhibits LPS-induced microglial activation[42][11]
Generate SPMs that resolve neuroinflammation[10]
Modulate Toll-like receptor signaling in glial cells[8]

3. Oxidative Stress: MODERATE EFFECT

Meta-analysis of 39 RCTs: omega-3s significantly increase total antioxidant capacity (TAC) and glutathione peroxidase (GPx) activity, and decrease malondialdehyde (MDA)[43]
EPA and DHA reduce cellular and mitochondrial ROS production[44][45]
Increase expression and activity of antioxidant enzymes (SOD, GPx, catalase)[44][45]
Activate Nrf2 antioxidant pathway[46]

4. Mitochondrial Dysfunction: MODERATE EFFECT

PA and DHA improve mitochondrial membrane potential[44][45]
Stimulate mitochondrial biogenesis through PGC-1α pathway[44][45][47]
Promote mitochondrial fusion over fission (healthier mitochondrial dynamics)[48]
Enhance oxidative phosphorylation and ATP production[44][45]
Reduce mitochondrial ROS production[44][45][48]

—

8. DOSING, TIMING, DURATION AND ADMINISTRATION

Recommended Dosing (Based on Human Studies):

General anti-inflammatory

EPA+DHA Dose: 1-2 g/day
Timing: With fatty meals
Duration: Ongoing

Rheumatoid arthritis

EPA+DHA Dose: 2.7-4 g/day
Timing: Divided doses with meals
Duration: Minimum 12 weeks

Migraine prevention

EPA+DHA Dose: 1.5-1.8 g/day EPA
Timing: With meals
Duration: Minimum 12-16 weeks

Dysmenorrhea

EPA+DHA Dose: 1-2 g/day
Timing: Daily, starting before menses
Duration: 2-3 months

Osteoarthritis

EPA+DHA Dose: 3-4 g/day
Timing: Divided doses with meals
Duration: Minimum 24 weeks

Key Dosing Points:

Anti-inflammatory threshold: ≥2 g/day EPA+DHA appears necessary for significant anti-inflammatory effects[24]
Meta-analysis suggests doses of 1-3 g/day are most consistently effective for reducing inflammatory markers[38]
Interestingly, one meta-analysis found lower doses (≤1.35 g/day) more effective for pain than higher doses, possibly due to better compliance or optimal dosing range[13]
Higher EPA:DHA ratios (≥1:1) may be more effective for reducing arachidonic acid and some inflammatory markers[38]
DHA-predominant formulations may be better for neurological conditions[39]

Timing:

Take with meals containing dietary fat (5 grams) to enhance absorption[20]
Divided doses (2-3 times daily) may improve tolerability and maintain stable blood levels
Enteric-coated formulations reduce fishy burps if taken without food

Duration of Onset:

Blood EPA/DHA levels increase within 1-2 weeks of supplementation[49]
Anti-inflammatory effects may take 4-8 weeks to manifest clinically
Pain benefits are time-dependent: greater at 6 months than at 1 month[13]
Allow minimum 12-16 weeks to assess clinical benefit for chronic pain conditions

—

9. FORMULATION CONSIDERATIONS

Fish Oil (Triglyceride Form):

Most common supplement form
Natural triglyceride form has good bioavailability[20]
Typical concentration: 30% EPA+DHA (1000 mg capsule = 300 mg EPA+DHA)
Concentrated fish oils available with 50-90% EPA+DHA

Ethyl Ester Form:

Used in prescription omega-3 products (Lovaza Rx)
Slightly lower bioavailability than triglyceride form, especially without food[20]
More concentrated formulations available

Re-esterified Triglyceride (rTG):

Concentrated fish oil converted back to triglyceride form
Better bioavailability than ethyl esters[20]
Higher cost

Krill Oil:

Phospholipid-bound omega-3s with potentially better bioavailability[21][22]
Contains astaxanthin (antioxidant)
Lower EPA+DHA content per capsule than fish oil
More expensive per gram of EPA+DHA

Algal Oil:

Vegan/vegetarian source of EPA and DHA
Comparable bioavailability to fish oil[23]
Sustainable and free of ocean contaminants
DHA-predominant formulations most common

Quality Considerations:

Choose products with third-party testing (USP, NSF, IFOS certification)
Check for oxidation markers (peroxide value, anisidine value)
Pharmaceutical-grade products have negligible mercury and contaminants[50][51]
Store in cool, dark conditions; refrigeration extends shelf life

—

10. SYNERGIES WITH OTHER PAIN MEDICATIONS AND NUTRACEUTICALS

Nutraceuticals with Potential Synergy:

Vitamin E: Protects omega-3s from oxidation; combination more effective for dysmenorrhea than either alone[52]
Curcumin: Complementary anti-inflammatory mechanisms; both inhibit NF-κB
Quercetin: Both reduce inflammatory cytokines and oxidative stress
Vitamin D: Synergistic anti-inflammatory effects; both support immune modulation
Glucosamine/Chondroitin: Complementary mechanisms for joint health
Resveratrol: Both activate SIRT1 pathway

Conventional Medications:

NSAIDs: Complementary mechanisms; omega-3s may allow NSAID dose reduction in some patients[15]
Gabapentinoids: No known interaction; complementary mechanisms
Duloxetine/SNRIs: May complement through different pathways
DMARDs (methotrexate): Safe to combine; may enhance anti-inflammatory effects[25]
Acetaminophen: No known interaction

—

11. DRUG INTERACTIONS

Clinically Significant Interactions:

Anticoagulants (Warfarin, DOACs) – MONITOR

Omega-3s may prolong bleeding time through antiplatelet effects[53]
Clinical trials have not shown significantly increased bleeding at doses 4 g/day, even with concurrent anticoagulants[54][50]
FDA labeling recommends periodic monitoring when combined with anticoagulants[53]
Use caution at high doses (>3 g/day)

Antiplatelet Agents (Aspirin, Clopidogrel) – MONITOR

Theoretical additive antiplatelet effect
Clinical studies show no significant increase in major bleeding at doses up to 4 g/day[54][51]
Monitor for signs of bleeding

Moderate Interactions (Generally Safe with Monitoring):

Blood Pressure Medications:

Omega-3s have modest blood pressure-lowering effects
May enhance antihypertensive effects; monitor blood pressure

Diabetes Medications:

High-dose omega-3s may slightly affect glycemic control in some patients
Monitor blood glucose, especially when initiating high-dose therapy

Generally Safe – No Known Significant Interactions:

Acetaminophen
Gabapentinoids (gabapentin, pregabalin)
Most antidepressants
Opioids
Proton pump inhibitors
Statins (may have complementary cardiovascular benefits)

—

12. SAFETY AND CONTRAINDICATIONS

Generally Favorable Safety Profile:

Omega-3 fatty acids are well-tolerated, with adverse effects occurring in 5% of patients.[16] Meta-analysis of 90 RCTs confirmed a favorable safety profile.[17]

Common Side Effects (Generally Mild):

]Fishy aftertaste/burps (most common)
Mild gastrointestinal discomfort (nausea, diarrhea)
Dyspepsia

Less Common Side Effects:

Increased LDL cholesterol (primarily with DHA)[16]
Atrial fibrillation (observed in high-dose cardiovascular trials: 5.3% vs 3.9% with placebo in REDUCE-IT)[16]
Bleeding tendency (odds ratio 1.26 vs placebo)[17]

Contraindications:

Known allergy to fish (though purified fish oils are typically not allergenic)[16]
Active bleeding disorders

Use with Caution:

Patients on anticoagulants or antiplatelet therapy – monitor for bleeding[53]
Patients with atrial fibrillation or at high risk – discuss with cardiologist
Pre-surgical patients – some surgeons recommend stopping 1-2 weeks before surgery
Seafood allergy – FDA recommends using under healthcare provider guidance[16]

Pregnancy and Lactation:

Generally considered safe and beneficial during pregnancy
DHA is important for fetal brain development
Avoid high-mercury fish; purified supplements are preferred

Long-Term Safety:

Extensive long-term safety data from cardiovascular trials
No evidence of carcinogenicity or serious organ toxicity
Mercury and contaminant concerns apply to fish consumption, not purified supplements[50][51]

—

13. SPECIAL CONSIDERATIONS / TIPS

Dose matters: Anti-inflammatory effects generally require ≥2 g/day of EPA+DHA. Standard fish oil capsules (1000 mg) typically contain only 300 mg EPA+DHA, so multiple capsules are needed.[24]
Be patient: Benefits are time-dependent, with greater effects at 6 months than at 1 month. Allow 12-16 weeks minimum to assess benefit.[13]
Take with food: Fat-containing meals significantly enhance absorption and reduce fishy burps.[20]
Consider the source: For therapeutic doses, supplements are more practical than diet alone. Two servings of fatty fish per week provides only ~500 mg/day EPA+DHA.[16]
Quality matters: Choose products with third-party certification (USP, NSF, IFOS) to ensure purity and potency.[51]
Reduce omega-6 intake: The omega-6:omega-3 ratio matters. Reducing vegetable oil (high in omega-6 linoleic acid) intake may enhance omega-3 benefits, particularly for migraine.[27]
For migraine: Higher EPA formulations (EPA:DHA ratio ≥2:1) may be more effective.[28]
For rheumatoid arthritis: Higher doses (2.7-4 g/day) and longer duration (≥12 weeks) show best results.[25][55]
Enteric coating: If fishy burps are problematic, enteric-coated formulations release in the intestine rather than stomach.
Storage: Store in a cool, dark place or refrigerate to prevent oxidation. Discard if oil smells rancid.
Anticoagulant caution: If taking warfarin or other blood thinners, inform your healthcare provider and monitor for signs of bleeding.[53]

—

14. COSTS

Standard fish oil (1000 mg capsules, 30% concentration): $10-20 per month
Concentrated fish oil (60-90% EPA+DHA): $25-50 per month
Prescription omega-3 products (Lovaza, Vascepa): $200-400 per month (may be covered by insurance for approved indications)
Krill oil: $20-40 per month
Algal oil (vegan): $25-50 per month

Omega-3 supplements are widely available over-the-counter and do not require a prescription. Costs vary significantly by brand, concentration, and formulation. Higher-concentration products may be more cost-effective when calculating price per gram of EPA+DHA.

—

Remember: Omega-3 fatty acids are among the most well-studied nutraceuticals for chronic pain, with the strongest evidence in rheumatoid arthritis, migraine, and dysmenorrhea. They work through multiple mechanisms—reducing inflammation, generating pro-resolving mediators, and modulating neuroinflammation—that address fundamental drivers of chronic pain.

Benefits are dose-dependent (generally ≥2 g/day EPA+DHA) and time-dependent (greater at 6 months than 1 month). The excellent safety profile and additional cardiovascular benefits make omega-3s a reasonable adjunctive therapy for many chronic pain conditions. The main limitations are the need for relatively high doses, slow onset of action, and variable evidence across different pain conditions.

Always discuss any new supplement with your healthcare provider, especially if you take anticoagulants or have a bleeding disorder.

The evidence is strongest for rheumatoid arthritis, migraine, and dysmenorrhea, with moderate effects on systemic inflammation and neuroinflammation. Key practical points include the need for therapeutic doses (≥2 g/day EPA+DHA), the time-dependent nature of benefits, and the importance of quality formulations.

References

N-3 PUFA and Inflammation: From Membrane to Nucleus and From Bench to Bedside. Calder PC. The Proceedings of the Nutrition Society. 2020;:1-13. doi:10.1017/S0029665120007077.
Omega-3 Fatty Acids and Inflammatory Processes: From Molecules to Man. Calder PC. Biochemical Society Transactions. 2017;45(5):1105-1115. doi:10.1042/BST20160474.
N-3 Polyunsaturated Fatty Acids, Inflammation, and Inflammatory Diseases. Calder PC. The American Journal of Clinical Nutrition. 2006;83(6 Suppl):1505S-1519S. doi:10.1093/ajcn/83.6.1505S.
Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?. Chávez-Castillo M, Ortega Á, Cudris-Torres L, et al. International Journal of Molecular Sciences. 2021;22(19):10370. doi:10.3390/ijms221910370.
The Mechanisms of Specialized Pro-Resolving Mediators in Pain Relief: Neuro-Immune and Neuroglial Regulations. Chen Y, Wu X, Li J, et al. Frontiers in Immunology. 2025;16:1634724. doi:10.3389/fimmu.2025.1634724.
Implications for Eicosapentaenoic Acid- And Docosahexaenoic Acid-Derived Resolvins as Therapeutics for Arthritis. Souza PR, Norling LV. European Journal of Pharmacology. 2016;785:165-173. doi:10.1016/j.ejphar.2015.05.072.
Immunomodulatory Effects of Omega-3 Fatty Acids: Mechanistic Insights and Health Implications. Bodur M, Yilmaz B, Ağagündüz D, Ozogul Y. Molecular Nutrition & Food Research. 2025;69(10):e202400752. doi:10.1002/mnfr.202400752.
Dietary Ω-3 Fatty Acids and Their Influence on Inflammation via Toll-Like Receptor Pathways. Jalili M, Hekmatdoost A. Nutrition (Burbank, Los Angeles County, Calif.). 2021;85:111070. doi:10.1016/j.nut.2020.111070.
Anti-Inflammatory Effects of Omega-3 Fatty Acids in the Brain: Physiological Mechanisms and Relevance to Pharmacology. Layé S, Nadjar A, Joffre C, Bazinet RP. Pharmacological Reviews. 2018;70(1):12-38. doi:10.1124/pr.117.014092.
N-3 Polyunsaturated Fatty Acids and the Resolution of Neuroinflammation. Joffre C, Rey C, Layé S. Frontiers in Pharmacology. 2019;10:1022. doi:10.3389/fphar.2019.01022.
Spinal Injection of Docosahexaenoic Acid Attenuates Carrageenan-Induced Inflammatory Pain Through Inhibition of Microglia-Mediated Neuroinflammation in the Spinal Cord. Lu Y, Zhao LX, Cao DL, Gao YJ. Neuroscience. 2013;241:22-31. doi:10.1016/j.neuroscience.2013.03.003.
Vesicular Nucleotide Transporter Is a Molecular Target of Eicosapentaenoic Acid for Neuropathic and Inflammatory Pain Treatment. Kato Y, Ohsugi K, Fukuno Y, et al. Proceedings of the National Academy of Sciences of the United States of America. 2022;119(30):e2122158119. doi:10.1073/pnas.2122158119.
Effects of Omega-3 Fatty Acids on Chronic Pain: A Systematic Review and Meta-Analysis. Xie L, Wang X, Chu J, et al. Frontiers in Medicine. 2025;12:1654661. doi:10.3389/fmed.2025.1654661.
Omega-3 Fatty Acids and Cardiovascular Disease: Effects on Risk Factors, Molecular Pathways, and Clinical Events. Mozaffarian D, Wu JH. Journal of the American College of Cardiology. 2011;58(20):2047-67. doi:10.1016/j.jacc.2011.06.063.
Influence of Marine N-3 Polyunsaturated Fatty Acids on Immune Function and a Systematic Review of Their Effects on Clinical Outcomes in Rheumatoid Arthritis. Miles EA, Calder PC. The British Journal of Nutrition. 2012;107 Suppl 2:S171-84. doi:10.1017/S0007114512001560.
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids: JACC Focus Seminar. Weinberg RL, Brook RD, Rubenfire M, Eagle KA. Journal of the American College of Cardiology. 2021;77(5):593-608. doi:10.1016/j.jacc.2020.11.060.
Safety of Supplementation of Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Chang JP, Tseng PT, Zeng BS, et al. Advances in Nutrition (Bethesda, Md.). 2023;14(6):1326-1336. doi:10.1016/j.advnut.2023.08.003.
Molecular Features, Effective Sources, and Physiological Effects of Omega-3 Unsaturated Fatty Acids on Cardiovascular, Neurological, and Muscular Health, and Clinical Relevance for Several Conditions: A Narrative Review. Vergara Nieto ÁA, Díaz AH, Hernández Millán M, Sagredo D. Nutrition Reviews. 2025;:nuaf201. doi:10.1093/nutrit/nuaf201.
n–3 Fatty Acids in Cardiovascular Disease. De Caterina R. The New England Journal of Medicine. 2011;364(25):2439-50. doi:10.1056/NEJMra1008153.
Bioavailability of EPA and DHA in Humans – A Comprehensive Review. Alijani S, Hahn A, Harris WS, Schuchardt JP. Progress in Lipid Research. 2025;97:101318. doi:10.1016/j.plipres.2024.101318.
Krill Oil for Knee Osteoarthritis: A Randomized Clinical Trial. Laslett LL, Scheepers LEJM, Antony B, et al. JAMA. 2024;331(23):1997-2006. doi:10.1001/jama.2024.6063.
Krill Oil Improved Osteoarthritic Knee Pain in Adults With Mild to Moderate Knee Osteoarthritis: A 6-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Stonehouse W, Benassi-Evans B, Bednarz J, et al. The American Journal of Clinical Nutrition. 2022;116(3):672-685. doi:10.1093/ajcn/nqac125.
Comparative Bioavailability of DHA and EPA From Microalgal and Fish Oil in Adults. Bailey E, Wojcik J, Rahn M, et al. International Journal of Molecular Sciences. 2025;26(19):9343. doi:10.3390/ijms26199343.
Omega-3 Polyunsaturated Fatty Acids and Inflammatory Processes: Nutrition or Pharmacology?. Calder PC. British Journal of Clinical Pharmacology. 2013;75(3):645-62. doi:10.1111/j.1365-2125.2012.04374.x.
Impact of Type and Dose of Oral Polyunsaturated Fatty Acid Supplementation on Disease Activity in Inflammatory Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. Sigaux J, Mathieu S, Nguyen Y, et al. Arthritis Research & Therapy. 2022;24(1):100. doi:10.1186/s13075-022-02781-2.
Effects of Omega-3 Supplementation on Lipid Metabolism, Inflammation, and Disease Activity in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials. Wang W, Xu Y, Zhou J, Zang Y. Clinical Rheumatology. 2024;43(8):2479-2488. doi:10.1007/s10067-024-07040-0.
Dietary Alteration of N-3 and N-6 Fatty Acids for Headache Reduction in Adults With Migraine: Randomized Controlled Trial. Ramsden CE, Zamora D, Faurot KR, et al. BMJ (Clinical Research Ed.). 2021;374:n1448. doi:10.1136/bmj.n1448.
A 12-Week Randomized Double-Blind Clinical Trial of Eicosapentaenoic Acid Intervention in Episodic Migraine. Wang HF, Liu WC, Zailani H, et al. Brain, Behavior, and Immunity. 2024;118:459-467. doi:10.1016/j.bbi.2024.03.019.
The Impact of Omega-3 Polyunsaturated Fatty Acids on Primary Dysmenorrhea: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mohammadi MM, Mirjalili R, Faraji A. European Journal of Clinical Pharmacology. 2022;78(5):721-731. doi:10.1007/s00228-021-03263-1.
Polyunsaturated Fatty Acids and Chronic Pain: A Systematic Review and Meta-Analysis. Prego-Dominguez J, Hadrya F, Takkouche B. Pain Physician. 2016 Nov-Dec;19(8):521-535.
Effect of Omega-3 Fatty Acids on Intensity of Primary Dysmenorrhea. Rahbar N, Asgharzadeh N, Ghorbani R. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2012;117(1):45-7. doi:10.1016/j.ijgo.2011.11.019.
Omega-3 Supplementation and Its Effects on Osteoarthritis. Shawl M, Geetha T, Burnett D, Babu JR. Nutrients. 2024;16(11):1650. doi:10.3390/nu16111650.
The Role of Nutraceuticals in Osteoarthritis Prevention and Treatment: Focus on N-3 PUFAs. Oppedisano F, Bulotta RM, Maiuolo J, et al. Oxidative Medicine and Cellular Longevity. 2021;2021:4878562. doi:10.1155/2021/4878562.
Omega-3 Fatty Acid Supplementation for Distal Symmetrical Peripheral Neuropathy in Adults With Diabetes Mellitus. Britten-Jones AC, Linstrom TA, Makrai E, et al. The Cochrane Database of Systematic Reviews. 2025;9:CD014623. doi:10.1002/14651858.CD014623.pub2.
Dietary Omega-3 Polyunsaturated Fatty-Acid Supplementation Upregulates Protective Cellular Pathways in Patients With Type 2 Diabetes Exhibiting Improvement in Painful Diabetic Neuropathy. Durán AM, Beeson WL, Firek A, Cordero-MacIntyre Z, De León M. Nutrients. 2022;14(4):761. doi:10.3390/nu14040761.
Dietary Docosahexaenoic Acid-Rich Supplementation Decreases Neurotoxic Lipid Mediators in Participants With Type 2 Diabetes and Neuropathic Pain. Durán AM, Zamora F, De León M. Nutrients. 2024;16(23):4025. doi:10.3390/nu16234025.
Acute Antinociceptive Effect of Fish Oil or Its Major Compounds, Eicosapentaenoic and Docosahexaenoic Acids on Diabetic Neuropathic Pain Depends on Opioid System Activation. Redivo DDB, Jesus CHA, Sotomaior BB, Gasparin AT, Cunha JM. Behavioural Brain Research. 2019;372:111992. doi:10.1016/j.bbr.2019.111992.
Role of the EPA: DHA Dosing Ratio in Omega-3 Supplements on Blood Fatty Acid Profiles and Inflammation: A Systematic Review and Meta-Analysis. Khabir Z, Abdelhafez A, Camponovo F, Joyce P, Garcia-Bennett A. Critical Reviews in Food Science and Nutrition. 2026;:1-22. doi:10.1080/10408398.2026.2615693.
A Randomized, Crossover, Head-to-Head Comparison of Eicosapentaenoic Acid and Docosahexaenoic Acid Supplementation to Reduce Inflammation Markers in Men and Women: The Comparing EPA to DHA (ComparED) Study. Allaire J, Couture P, Leclerc M, et al. The American Journal of Clinical Nutrition. 2016;104(2):280-7. doi:10.3945/ajcn.116.131896.
Beneficial Effects of Fish Oil Enriched in Omega-3 Fatty Acids on the Development and Maintenance of Neuropathic Pain. Unda SR, Villegas EA, Toledo ME, Asis Onell G, Laino CH. The Journal of Pharmacy and Pharmacology. 2020;72(3):437-447. doi:10.1111/jphp.13213.
N-3 Polyunsaturated Fatty Acids in Animal Models With Neuroinflammation: An Update. Trépanier MO, Hopperton KE, Orr SK, Bazinet RP. European Journal of Pharmacology. 2016;785:187-206. doi:10.1016/j.ejphar.2015.05.045.
Omega-3 Polyunsaturated Fatty Acids Suppress the Inflammatory Responses of Lipopolysaccharide-Stimulated Mouse Microglia by Activating SIRT1 Pathways. Inoue T, Tanaka M, Masuda S, et al. Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids. 2017;1862(5):552-560. doi:10.1016/j.bbalip.2017.02.010.
Omega-3 Fatty Acids Supplementation and Oxidative Stress Parameters: A Systematic Review and Meta-Analysis of Clinical Trials. Heshmati J, Morvaridzadeh M, Maroufizadeh S, et al. Pharmacological Research. 2019;149:104462. doi:10.1016/j.phrs.2019.104462.
Eicosapentaenoic Acid (EPA) Exhibits Antioxidant Activity via Mitochondrial Modulation. Xiao B, Li Y, Lin Y, et al. Food Chemistry. 2022;373(Pt A):131389. doi:10.1016/j.foodchem.2021.131389.
Antioxidant Activity of Docosahexaenoic Acid (DHA) and Its Regulatory Roles in Mitochondria. Li G, Li Y, Xiao B, et al. Journal of Agricultural and Food Chemistry. 2021;69(5):1647-1655. doi:10.1021/acs.jafc.0c07751.
Efficacy of Omega-3 Fatty Acids as a Functional Food: A Multifaceted Approach to Health Reinforcement. Ahmad MF, Alsayegh AA, Khanam A, et al. Journal of the Science of Food and Agriculture. 2025;. doi:10.1002/jsfa.70346.
Skeletal Muscle Protein Turnover and Mitochondrial Responses to Omega-3 Fatty Acid Supplementation: An Update. Hayden JE, Deane CS. Current Opinion in Clinical Nutrition and Metabolic Care. 2026;:00075197-990000000-00271. doi:10.1097/MCO.0000000000001196.
High-Fish Oil and High-Lard Diets Differently Affect Testicular Antioxidant Defense and Mitochondrial Fusion/Fission Balance in Male Wistar Rats: Potential Protective Effect of Ω3 Polyunsaturated Fatty Acids Targeting Mitochondria Dynamics. Migliaccio V, Sica R, Di Gregorio I, Putti R, Lionetti L. International Journal of Molecular Sciences. 2019;20(12):E3110. doi:10.3390/ijms20123110.
The Relationship Between Fatty Acids and the Development, Course and Treatment of Rheumatoid Arthritis. Tański W, Świątoniowska-Lonc N, Tabin M, Jankowska-Polańska B. Nutrients. 2022;14(5):1030. doi:10.3390/nu14051030.
Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Journal of the American College of Cardiology. 2009;54(7):585-94. doi:10.1016/j.jacc.2009.02.084.
Safety Considerations With Omega-3 Fatty Acid Therapy. Bays HE. The American Journal of Cardiology. 2007;99(6A):35C-43C. doi:10.1016/j.amjcard.2006.11.020.
Vitamin E and Fish Oil, Separately or in Combination, on Treatment of Primary Dysmenorrhea: A Double-Blind, Randomized Clinical Trial. Sadeghi N, Paknezhad F, Rashidi Nooshabadi M, et al. Gynecological Endocrinology : The Official Journal of the International Society of Gynecological Endocrinology. 2018;34(9):804-808. doi:10.1080/09513590.2018.1450377.
Omega-3-acid ethyl esters. Food and Drug Administration. Updated date: 2021-05-26.
Cardiovascular Effects of Marine Omega-3 Fatty Acids. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Lancet (London, England). 2010;376(9740):540-50. doi:10.1016/S0140-6736(10)60445-X.
Effect of Ω-3 Polyunsaturated Fatty Acids on Arthritic Pain: A systematic Review. Abdulrazaq M, Innes JK, Calder PC. Nutrition (Burbank, Los Angeles County, Calif.). 2017 Jul – Aug;39-40:57-66. doi:10.1016/j.nut.2016.12.003.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.